ECCMID

In a report published Friday, Brean Capital analyst Jonathan Aschoff said that that Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) is a "prime takeout candidate" as the company continues to target NDA submission for eravacycline for both indications (cUTI and cIAI) by the end of 2015...